Economics of unfractionated heparin: beyond acquisition cost.

Abstract

Despite numerous clinical trials demonstrating advantages of new anticoagulants, unfractionated heparin (UFH) is still used by a number of clinicians in the United States. The reason for this continued use of UFH is not superior efficacy, improved safety, or convenience, but low acquisition cost. However, several other costs associated with the use of UFH are often not considered. Appropriate economic analysis, which considers both cost and outcomes, has not demonstrated support for continued use of UFH. Its continued use based simply on lower cost is not justified by the literature.